Product news from the 01/09/07 news brief

Share this article:
The FDA has approved MedImmune’s new refrigerated formulation of FluMist (influenza virus vaccine, intranasal) for use in helping to prevent influenza in healthy children and adults ages 5-49. The FDA approved Pfizer’s Slentrol (dirlotapide) for the management of obesity in dogs. Slentrol should be available in the spring according to Pfizer Animal Health. The once-daily drug should cost between $1 and $2 a dose. Stephen Sundlof, director of Center of Veterinary Medicine at the FDA, called Slentrol “a welcome addition to animal therapies because dog obesity appears to be increasing.” Veterinarians generally define a dog that weighs 20 % more than its ideal weight as obese. Surveys have found that approximately 5% of dogs in the US are obese and another 20-30% are overweight. The 180-day exclusivity period for Pfizer antidepressant Zoloft is set to expire next month. That means generics firm Ivax Pharmaceuticals—the only firm permitted to market generic Zoloft since the drug went off patent last year—will be joined by several competitors in offering low-cost copies. Generics companies that have received tentative approval to sell additional copies once Ivax’s six-month window expires include Dr. Reddy’s Laboratories, Genpharm, Mylan, Roxane and Apotex. Cubist Pharmaceuticals reported that fourth-quarter US sales of its antibiotic Cubicin, used to treat staph infections of the skin and blood, jumped 54%. Fourth quarter sales increased to $56.2 million, from $36.6 million during the same period in 2005. Full-year sales totaled $189.5 million, up 67% from 2005 sales of $113.5 million. Cubist is scheduled to report fourth quarter sales and full-year earnings results on Jan. 24.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.